Best Small Cap Stocks this May 2026 in the UK

Atlantic Lithium is focused on exploring and developing lithium assets in West Africa, positioning itself as a key player in the growing lithium market. Despite a challenging five-year return of -27.23%, the company has delivered an impressive one-year return of 133.75%. With a market capitalization of £129.9 million, it offers UK investors an opportunity in a sector poised for significant growth.

Luceco, with a market cap of £289.1 million, specializes in designing and distributing wiring accessories, LED lighting, and portable power products. This top-rated investment offers a solid dividend yield of 3.11% and has delivered a remarkable 58.61% return over the past year, although its five-year performance has seen a decline of 33.96%. Ideal for investors seeking reliable income from financially healthy companies, Luceco stands out in the market for its innovative product offerings and robust analyst ratings.

AFC Energy, a small-cap company valued at under £400 million, is backed by City Bank, presenting a strong potential for growth. With a remarkable 1-year return of 122.33%, the company is launching "Hy-5," the first containerized portable hydrogen power generation technology, signaling its commitment to innovation in the sector. Despite a challenging 5-year performance with a decline of 78.91%, the recent developments suggest promising prospects for investors.

AFC Energy has launched 'Hy-5', the world's first containerized, portable hydrogen cracking module, which can produce up to 500kg of hydrogen per day, set for delivery in 2026.

Harbour Energy (HBR) has a consensus rating of 'Buy' from 11 analysts, with 6 recommending a buy, 4 suggesting a hold, and 1 advising to sell.

AFC Energy is committed to high standards of environmental protection and sustainability.

PureTech Health has been recognized as a strong growth potential candidate among small-cap shares for 2026, despite its recent performance showing a -1.80% return over the past year and a substantial -70.16% decline over five years. Analysts maintain a consensus "Strong Buy" rating, with a median 12-month price target of $57.00, suggesting significant upside potential. This company could be an attractive option for investors looking to capitalize on promising growth in the biotech sector.

The consensus rating for PureTech Health (PRTC) is a 'Strong Buy,' with one analyst recommending a buy and none suggesting a sell or hold.

PureTech Health Plc shows mixed signals; it has a sell signal from the short-term moving average but a buy signal from the long-term average, indicating a generally positive outlook.

Tristel, a leader in infection prevention products for healthcare facilities, boasts a market cap of £196.5 million and has garnered a "Strong Buy" consensus rating from analysts. With a dividend yield of 3.74% and a solid history of consistent payouts, it's an attractive option for investors seeking reliable income. Despite a challenging five-year return of -35.44%, the average 12-month price target of £471.43 suggests potential for recovery, making it a stock worth considering.

Tristel has a consensus rating of 'Strong Buy' from 7 analysts, with 6 recommending to buy, none suggesting to sell, and 1 advising to hold.

Tristel typically pays 2 dividends per year, with a dividend cover of approximately 2.0.

Analysts project an average 12-month price target of 471.43 GBP for Tristel, with estimates ranging from a low of 400 GBP to a high of 560 GBP.

Tristel generates revenue by selling its proprietary chlorine dioxide chemistry for decontaminating medical devices and for sporicidal disinfection of surfaces.